Aoxiang Pharmaceutical's announcement on using part of idle raised funds to temporarily supplement working capital
Securities code: 603229 Securities abbreviation: Aoxiang Pharmaceutical Announcement number: 2026-017
Zhejiang Aoxiang Pharmaceutical Co., Ltd.
Regarding the use of part of idle raised funds
Announcement on temporary replenishment of working capital
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Amount of funds raised through temporary supplementary flow: 150 million yuan
Replenishment period: no more than 12 months from the date of review and approval at the 11th meeting of the fourth board of directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") on April 27, 2026
1. Basic situation of raised funds
Issuance Name 2022 Non-Public Issuance of Stocks
Total amount of funds raised 484.9031 million yuan Net amount of funds raised 473.9338 million yuan Time of receipt of funds raised January 18, 2023
RMB 10 million will be returned on February 25, 2026;
Used to temporarily replenish working capital last time
140 million yuan will be returned on April 24, 2026;
The date and amount of return of raised funds
All funds raised from the previous temporary supplement of working capital have been returned.
2. Basic situation of investment projects with raised funds
As of December 31, 2025, the basic situation of the company's 2022 non-public issuance of stock investment projects is as follows:
Issuance Name 2022 Non-Public Issuance of Stocks
Raised funds account balance [note] 75.5018 million yuan
Amount of investment of raised funds Raised funds used
Fundraising project name Project progress (%)
(10,000 yuan) Amount (10,000 yuan)
High-end preparation internationalization project (Phase I) 27,903.07 13,527.52 48.48 Featured raw materials and key pharmaceutical centers
13,000.00 5,871.76 45.17 Industrialization Project (Phase II)
Supplementary flow project 6,490.31 6,512.32 100.34 Total 47,393.38 25,911.60 —
[Note] The "raised capital account balance" refers to the raised capital bank account balance as of December 31, 2025, excluding the temporary supplementary working capital of 150 million yuan that has not expired as of that date.
3. This time’s plan to use part of the idle raised funds to temporarily supplement working capital
In order to improve the efficiency of the use of raised funds, reduce financial expenses, reduce the company's operating costs, and safeguard the interests of the company and all shareholders, and on the premise of ensuring the normal progress of the fund demand for the construction of investment projects with raised funds and the plan for the use of raised funds, the company and its wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd. plan to use idle raised funds not exceeding RMB 150 million to temporarily supplement working capital. The use period shall not exceed 12 months from the date of approval by the company's board of directors, and will be returned to the corresponding raised funds account upon expiration.
The use of part of the idle raised funds to temporarily replenish working capital this time is limited to production and operations related to the main business, and is implemented through a special account of raised funds. It will not change the purpose of the raised funds, and will not affect the normal progress of the investment plan of the raised funds; it will not be used for the allotment and subscription of new shares through direct or indirect arrangements, or for transactions such as stocks and their derivatives, convertible corporate bonds, etc., and there will be no harm to the interests of shareholders.
- The board of directors’ review process for this plan to temporarily replenish working capital with part of the idle raised funds and whether it meets regulatory requirements
On April 27, 2026, the company held the 11th meeting of the fourth board of directors, and reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital", agreeing that the company and its subsidiaries will use idle raised funds not exceeding RMB 150 million to temporarily supplement working capital. This matter does not need to be submitted to the shareholders' meeting for review.
The company and its subsidiaries used part of the idle raised funds to temporarily replenish working capital this time, which complies with the provisions of relevant laws and regulations such as the "Supervisory Rules for Funds Raised by Listed Companies", "Stock Listing Rules of the Shanghai Stock Exchange", "Self-Discipline Supervision Guidelines for Listed Companies of the Shanghai Stock Exchange No. 1 - Standardized Operations", and meets regulatory requirements.
5. Explanation of special opinions
After verification, the sponsor believes that the company and its subsidiaries plan to use no more than 150 million yuan of idle raised funds to temporarily replenish working capital, which has been reviewed and approved at the 11th meeting of the company's fourth board of directors, and has fulfilled the corresponding legal procedures and complies with relevant regulations such as the "Supervisory Rules for Listed Companies' Raised Funds", "Shanghai Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 1 - Standardized Operations" and the company's "Raised Funds Management System".
Based on the above opinions, the sponsor has no objection to the company and its subsidiaries using part of the idle raised funds to temporarily supplement working capital.
Announcement is hereby made.
Board of Directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd.
April 29, 2026